Literature summary for 3.4.21.68 extracted from

Su, L.; Xu, X.; Zhao, H.; Gu, Q.; Zou, H.
In vitro and in vivo antiangiogenic activity of a novel deca-peptide derived from human tissue-type plasminogen activator kringle 2 (2010), Biochem. Biophys. Res. Commun., 396, 1012-1017.

Search for more literature for 3.4.21.68

Protein Variants

Protein Variants	Comment	Organism
additional information	a synthetic deca-peptide corresponding to the amino acid sequence Arg54-Trp63 of human tissue-type plasminogen activator kringle 2 domain, named TKII-10, is produced and tested for its ability to inhibit endothelial cell proliferation, migration, tube formation in vitro, and angiogenesis in vivo. Another peptide TKII-10S, composed of the same 10 amino acids as TKII-10 but in a different sequence, is also produced and tested, showing that TKII-10 potently inhibits VEGF-stimulated endothelial cell migration and tube formation in a dose-dependent, as well as sequence-dependent manner in vitro while it is inactive in inhibiting endothelial cell proliferation. Furthermore, TKII-10 potently inhibits angiogenesis in chick chorioallantoic membrane and mouse cornea. The middle four amino acids DGDA in their sequence play an important role in TKII-10 angiogenesis inhibition	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining

Synonyms

Synonyms	Comment	Organism
t-PA	-	Homo sapiens
Tissue-type plasminogen activator	-	Homo sapiens

General Information

General Information	Comment	Organism
additional information	the synthetic deca-peptide corresponding to the amino acid sequence Arg54-Trp63 of human tissue-type plasminogen activator kringle 2 domain, i.e. TKII-10, effectively inhibits VEGF-stimulated HUVECs migration and tube formation, but it demonstrats no inhibitory effect on VEGF-stimulated HUVECs proliferation, overview. TKII-10 effectively inhibits angiogenesis in vivo	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)